IMNM FY 2021 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$25M

Net Income

-$25M

EPS (Diluted)

$-2.14

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$58M

Total Liabilities

$10M

Stockholders' Equity

$48M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$755,000	+100.0%
Operating Income	-$25M	-$12M	-105.6%
Net Income	-$25M	-$18M	-38.5%